The first case of the acquisition of the pharmaceutical industry in the year of the tiger was spent on stone medicine.
CSPC Pharmaceutical Group announced on February 8 that it had acquired 100% of the equity of Zhuhai Zhifan Enterprise Management Consulting Center. Zhuhai Zhifan is a platform company, mainly holding about 51% of the total registered capital of Guangzhou Mingkang Biological Engineering Co., Ltd.
That is to say, through the acquisition of Zhuhai Zhifan, CSPC actually controlled Guangzhou Mingkang Biology.
Mingkang Bio was established in 2000, and its core product is "Ming fu le", that is, recombinant human TNK tissue type plasminogen activator. This is a third-generation specific thrombolytic drug, mainly used for the treatment of patients within 6 hours of the onset of acute myocardial infarction.
CSPC has previously accumulated deep accumulation in the field of cardiovascular and cerebrovascular diseases, and "Enbipu" is the first new drug of class 1 in the field of cardiovascular and cerebrovascular diseases in China. After the acquisition of Guangzhou Mingkang, "Ming Fu Le" will become another blockbuster product of stone medicine. CSPC officials said that "Ming Fu Le" has good commercial potential, and the acquisition will provide new growth momentum for the company.
Break the monopoly of foreign capital and develop indications for myocardial infarction
Mingkang Bio's "Ming Fu Le" is a three-generation specific thrombolytic drug, which belongs to the first aid drug of myocardial infarction. Thrombolytic drugs are roughly divided into three generations, and the largest amount of domestic hospitals is the second generation of drugs, representing the variety of Alteplase original research by Boehringer Ingelheim.
In June 2017, the Qilu Evening News reported that Professor Liu Guoen, director of the China Health Economic Research Center at Peking University, said: "The study shows that the total cost of hospitalization of patients using the second-generation thrombolytic drug alteplase is 49,500 yuan. ”
China has been carrying out the research and development of three generations of thrombolytic drugs, hoping to replace the second generation of drugs. In January 2015, Guangzhou Mingkang Bio's "Ming Fu Le" was approved for listing, filling the gap in the market.
In December 2020, "Ming Fu Le" entered medical insurance through price negotiations, and the winning bid price was 3688 yuan per bottle.
According to the announcement of CSPC, the indications for cerebral infarction thrombolysis are also under development, and have been carried out to the third stage, as of January 28, 2022, 61 research centers have been launched, and 1362 patients have been enrolled. In the future, "Ming Fu Le" may become a thrombolytic drug that can be used for myocardial infarction and cerebral infarction. This may be exactly where CSPC Group looks.
In addition to "Ming Fu Le", the varieties under study of Ming Kang Bio also include another anti-thrombotic drug recombinant hirudin, and a whitening drug rhGM-CSF, which is currently in the clinical stage.
The cardiovascular and cerebrovascular plates are completed, and innovative varieties are concentrated
At present, in the shareholding structure of Mingkang Biologics, Kangchen Pharmaceutical also holds 3.75% of the shares. It can be seen that it is not only the stone medicine family that is optimistic about Mingkang.
Mingkang Biology is facing the domestic thrombolytic drug market occupied by alteplase and three generations of imported drugs, retiplase. Although "Ming Fule" has entered the medical insurance, the promotion pressure will still be very large, and it will also face the impact of the imported variety of alteplase in the same medical insurance.
However, on the side of CSPC, "Ming Fu Le" constitutes an important part of the spectrum of CYPC cardiovascular and cerebrovascular drugs. "Enbipu" is mainly used for acute ischemic stroke, while "Ming fule" is mainly used for acute myocardial infarction, and the two drugs can basically cover the treatment of acute cardiovascular and cerebrovascular diseases.
After the listing of "Ming fu le", the market did not do well, and once entrusted foreign giants to act as agents for sales, but they failed to open up the situation. This is also a pain point that domestic innovative drug companies often encounter: excellent products lack excellent market promotion.
CSPC itself has a strong sales ability in the field of cardiovascular and cerebrovascular diseases, and in the hands of CSPC, the market performance of "Ming Fu Le" is expected to be greatly improved.
At the same time, "Ming Fu Le" also constitutes an important part of the cardiovascular product line of CSPC, which will have a strong synergy with the company's core variety Enbipu, so that the time threshold for the treatment of stroke of the company's products will be moved forward. At present, CSPC Pharmaceutical Group has about 300 research projects, including more than 40 small molecule and large molecule innovative drugs, and more than 30 new preparation drugs. Anti-tumor, immune, cardiovascular and cerebrovascular system and anti-infection treatment areas are the key research and development directions. According to the planning of CSPC, more than 30 innovative drugs and new formulations are expected to be listed in the next five years.
Through the acquisition of supplementary pipelines, it has always been one of the strategies of CSPC to seek acquisition targets with strong R&D capabilities in related fields. At the beginning of 2019, CSPC acquired Jinmante and obtained two monoclonal antibodies under research, which are also two key varieties that CSPC is optimistic about.
The acquisition of the equity of Mingkang Bio also marks a big step forward in CSPC's innovative drug strategy.